Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) Follow-on Study

Trial Profile

Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) Follow-on Study

Recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs AR 101 (Primary)
  • Indications Peanut hypersensitivity
  • Focus Adverse reactions
  • Acronyms PALISADE
  • Sponsors Aimmune Therapeutics
  • Most Recent Events

    • 15 Mar 2017 According to an Aimmune Therapeutics media release, the first patient was enrolled into the study in December 2016.
    • 16 Feb 2017 According to an Aimmune Therapeutics media release, the company expects that a potential BLA for AR101 would include safety data from at least 600 patients in the PALISADE, ARC004 and RAMSES trials.
    • 20 Jan 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top